Addex Therapeutics Ltd: Business Overview, Financials & Competitive Analysis

Addex Therapeutics Ltd Overview

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. The company was founded in 2002 and is based in Geneva, Switzerland. The company pursues multiple CNS indications through both proprietary and partnered programs.

Strategic Profile

The company has license and collaboration agreements with Janssen Pharmaceuticals Inc. for mGlu2 PAM compounds and with Indivior PLC for GABAB PAM compounds. Lead drug candidates include ADX71149, developed in partnership with Janssen for epilepsy treatment, and dipraglurant for Parkinson's disease levodopa-induced dyskinesia and post-stroke/TBI recovery. The partnership model provides both clinical validation and funding runway.

Competitive Landscape

Addex competes in the CNS drug development space against larger pharma companies and other biotech developers of novel neurological treatments. The allosteric modulator approach represents a differentiated mechanism potentially offering advantages over conventional orthosteric drugs. Key competitors include both established pharmaceutical companies and clinical-stage biotechs pursuing epilepsy, Parkinson's disease, and pain indications.

Industry Context

Addex Therapeutics Ltd operates in Biopharmaceuticals / Clinical-Stage Drug Development.

Key facts

Founded: 2002 · Headquarters: Geneva, Switzerland · Employees: 2 · Revenue: $0.47M · Market cap: $14.7M